the combination is the thing with trial data behind it, monotherapy in here is mostly us guessing, thats just me
#cagrilintide 2026-02-20
Friday47 messages9 participantstimes are UTC
Highlights from this day
- alt_ast_ali — $94 for a 15 vial and it lasts me longer than the GLP-1 does at my doses 17:59
- zoya_zeros — the fullness effect hasnt faded over 15 months, unlike my semaglutide appetite curve 19:43
- triumph_watch — its an amylin analogue, different receptor family, so treating it as another GLP-1 is the first mistake 21:19
- cold_chain_cmdr — the slower titration in here is community habit as much as anything, the trials had their own schedule 22:44
REDEFINE is the trial
slower than the others
weekly for me, same day every week, no reason beyond habit
noticed something around week 32 on monotherapy, well after i had given up expecting to
does the fullness effect fade the way appetite suppression does
did anyone add this to an existing tirzepatide dose rather than starting both
i said earlier this year that monotherapy did nothing for me, and at a higher dose it did something
dropped the GLP-1 and stayed on this alone for 17 months, appetite held but weight barely moved
anyone stopped the GLP-1 and kept only this
quick one stopped for 15 months and the fullness went within a fortnight of the last dose
unrelated but is the slower titration because of nausea or something else
*VendorInvestigate not the other one
underwhelming honestly
combination for me
thats the phase 3 one
$94 for a 15 vial and it lasts me longer than the GLP-1 does at my doses
👍10
monotherapy did work for me, just slower and smaller than i expected, thats one data point
monotherapy here
👍3🤝2
cant separate them
coming back to this is the nausea profile genuinely different or am i imagining it
whats REDEFINE testing exactly
titrating dead slow
how do people separate which of the two is doing what in a combination
genuine question REDEFINE is the phase 3 programme, most of what gets quoted casually in here is earlier work
the reason nausea reads differently is timing, mine arrived on the second day rather than the first
🙏1💀6
different not less
does amylin do something about fullness that the GLP-1 doesnt
30 in 5ml gives 8mg/ml which is what i use, purely because the units come out round
went slower because the first step gave me two rough days and i took that as information
did the combination change your GI compared to the GLP-1 alone
anyone holding at 0.25 for a while before stepping
did anyone find monotherapy underwhelming
the fullness effect hasnt faded over 15 months, unlike my semaglutide appetite curve
lot-log.csv
585 rows · not retained in the public archive
amylin is about slowed gastric emptying and satiety signalling, thats the short version and im no pharmacologist, i could be wrong
the numbers everyone quotes come from the combination, so comparing them to monotherapy logs is unfair
i was sceptical about monotherapy and after 23 months im still sceptical, just less so
is the weekly schedule the same here
held mine a while
separate days
cagrisema thats it
*that should say weekly
15 in 2ml gives 8mg/ml which is what i use, purely because the units come out round
the fullness thing is the part people describe differently, food stops being interesting rather than repellent
the nausea felt different rather than less, more fullness and less of the queasy wave
its an amylin analogue, different receptor family, so treating it as another GLP-1 is the first mistake
📉17
held at 15 for 6 months on monotherapy before i touched it again
amylin not glp-1
two PeptideMeter results on the same SGN lot came back 99 and 97.4, closer than i expected
the slower titration in here is community habit as much as anything, the trials had their own schedule
👀3🔥17